Oncology – Page 7

Unraveling the Role of LINC01521 in Papillary Thyroid Carcinoma: Prognostic Potential and Molecular Mechanisms

By MedXY 09/20/2026

LINC01521 is significantly upregulated in papillary thyroid carcinoma, promoting tumor progression by targeting miR-4319 and inhibiting cuproptosis, thereby serving as an independent prognostic marker for adverse clinical outcomes.

Cardiology news Oncology

Breast Cancer-Derived ADAM10: A Novel Mediator of Atrial Fibrillation Through Atrial Fibrosis

By MedXY 09/20/2026

Breast cancer independently increases atrial fibrillation risk via tumour-secreted ADAM10, which induces atrial fibrosis through the Ephrin B2 signaling pathway, offering a potential new therapeutic target.

$Prognostic Factors and Role of Allo-HSCT in First Salvage Therapy for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Treated with Blinatumomab and Inotuzumab Ozogamicin$

Hematology-Oncology news Oncology

Prognostic Factors and Role of Allo-HSCT in First Salvage Therapy for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Treated with Blinatumomab and Inotuzumab Ozogamicin

By MedXY 09/20/2026

Early measurable residual disease (MRD) negativity and timing of relapse are crucial for risk stratification in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) treated with blinatumomab and/or inotuzumab ozogamicin. Allogeneic stem cell transplantation (allo-HSCT) benefits select high-risk patients.

General Surgery news Oncology

Colovac Device vs Diverting Loop Ileostomy: A Prospective Pooled Analysis in Rectal Cancer Surgery

By MedXY 09/19/2026

This pooled analysis evaluates the safety and effectiveness of the Colovac Anastomosis Protection Device compared to standard diverting loop ileostomy following low anterior resection for rectal cancer, showing comparable major complication and anastomotic leak rates and significant potential to avoid ostomy.

news OB/GYN & Women's Health Oncology

Molecular Stratification of Early-Stage Vulvar Squamous Cell Carcinoma: Prognostic Impact of HPV and TP53 Status

By MedXY 09/19/2026

This study highlights how HPV and TP53 molecular subtyping in stage I vulvar squamous cell carcinoma delineates survival outcomes and recurrence risks, supporting its role in personalized management strategies.

Cardiology news Oncology

Proteomic and Metabolomic Insights into Cardiac Remodeling in Breast Cancer Patients Undergoing Cardiotoxic Therapy

By MedXY 09/19/2026

This study identifies novel proteomic and metabolomic biomarkers linked to cardiac dysfunction and remodeling in breast cancer patients treated with cardiotoxic therapies, revealing potential pathways for early detection and intervention.

Clinical Updates news Oncology

Optimizing Palliative Care for Effective Hospice Transitions in Cancer Patients: Insights from Multicenter Qualitative and Quantitative Evidence

By MedXY 09/18/2026

This review synthesizes evidence identifying critical programmatic factors, relational dynamics, and interventions enhancing hospice transitions in cancer palliative care, emphasizing collaborative oncology-palliative care relationships and integrated supportive strategies.

Gastroenterology news Oncology

Rising Early-Onset Colorectal Cancer and Persistent Racial Disparities Despite Increased Colonoscopy Use

By MedXY 09/18/2026

From 2017 to 2023, colonoscopy use increased notably in adults under 50. Yet, early-onset colorectal cancer rates and racial disparities, particularly among Black and Hispanic populations, worsened, highlighting that screening alone does not resolve these inequities.

Hematology-Oncology news Oncology

Evaluating Myeloablative Treosulfan-Fludarabine Conditioning in AML: A Promising Alternative for Middle-Aged Adults

By MedXY 09/18/2026

A phase II trial demonstrates the safety and efficacy of myeloablative-dose treosulfan plus fludarabine (FT14) conditioning in AML patients aged 40-65, showing high leukemia-free survival and low toxicity, supporting its use over busulfan regimens in selected cases.

$Five-Year Survival and Durable Remission with Lisocabtagene Maraleucel in Relapsed/Refractory Large B-Cell Lymphoma: Insights from the TRANSCEND NHL 001 Study$

Hematology-Oncology news Oncology

Five-Year Survival and Durable Remission with Lisocabtagene Maraleucel in Relapsed/Refractory Large B-Cell Lymphoma: Insights from the TRANSCEND NHL 001 Study

By MedXY 09/18/2026

Lisocabtagene maraleucel demonstrates durable five-year survival and potential cure in relapsed/refractory large B-cell lymphoma, with manageable long-term safety, based on data from the TRANSCEND NHL 001 trial and its long-term follow-up.

Hematology-Oncology news Oncology

NF-κB Driven Transcriptional Signatures in CAR-T Cells Predict Durable Responses in Multiple Myeloma

By MedXY 09/17/2026

Single-cell transcriptomic profiling of ide-cel CAR-T products reveals that intrinsic NF-κB signaling in CD4 CAR-T cells correlates with durable remission in relapsed/refractory multiple myeloma, marking T-cell fitness and potential therapeutic targets for enhancing CAR-T efficacy.

Diabetes & Endocrinology news Oncology

Reevaluating Radioactive Iodine Therapy in T3b Differentiated Thyroid Cancer: Insights from a SEER-Based Cohort Study

By MedXY 09/17/2026

This cohort study of 6,638 T3b differentiated thyroid cancer patients found no survival benefit from adjuvant radioactive iodine therapy, suggesting the need for individualized treatment strategies and prospective studies focusing on recurrence outcomes.

General Surgery news Oncology

Enhancing Survivorship: Multidisciplinary Rehabilitation Improves Cardiorespiratory Fitness in Upper Gastrointestinal Cancer Surgery Patients

By MedXY 09/17/2026

RESTORE II RCT demonstrates that a 12-week multidisciplinary rehabilitation program significantly improves cardiorespiratory fitness in survivors of upper gastrointestinal cancer surgery, supporting its integration in post-oncologic care.

news Oncology

Trogocytosis-Mediated CLDN18.2 Acquisition by CD8+ T Cells Impairs Anti-Tumor Immunity and Drives Pancreatic Cancer Progression

By MedXY 09/17/2026

This study reveals that CLDN18.2 acquired by CD8+ T cells through trogocytosis impairs their glucose metabolism and cytotoxic function, promoting pancreatic cancer progression and systemic immune senescence. Targeting this axis may enhance immunotherapy efficacy in PDAC.

Hematology-Oncology news Oncology

ATG versus Alemtuzumab for GvHD Prophylaxis in AML Allo-HCT: Insights from the EBMT Registry

By MedXY 09/16/2026

In AML patients undergoing unrelated donor allo-HCT with intermediate-intensity conditioning, ATG-based GvHD prophylaxis demonstrated better overall and leukemia-free survival and reduced relapse compared to alemtuzumab, despite higher acute GvHD incidence.

Hematology-Oncology news Oncology

Comparing CHOP and CHOEP/EPOCH Regimens in Aggressive Adult T-Cell Leukemia/Lymphoma: Insights from an International Cohort Study

By MedXY 09/16/2026

This international cohort study evaluates the effectiveness of CHOEP/EPOCH versus CHOP chemotherapy in aggressive adult T-cell leukemia/lymphoma, revealing subtype-specific survival benefits in lymphomatous ATL but inconclusive results in acute ATL.

news Oncology Otorhinolaryngology

Outcomes of Laryngeal Carcinoma Treatment in Female Patients: A Multicenter Retrospective Analysis

By MedXY 09/15/2026

This study evaluates clinical characteristics and treatment outcomes of female laryngeal cancer patients, highlighting better survival with surgical therapy compared to non-surgical approaches, and emphasizing the need for sex-specific treatment considerations.

General Surgery news Oncology

Real-World Five-Year Survival After Neoadjuvant Therapy and Surgery in Localized Pancreatic Ductal Adenocarcinoma

By MedXY 09/15/2026

This study reveals that over one-third of patients with localized PDAC receiving neoadjuvant therapy and surgery achieve actual five-year survival, highlighting the impact of early systemic failure and identifying factors predicting long-term outcomes.

Gastroenterology news Oncology

New International Consensus: Colorectal Cancer Risk in MASLD — What Clinicians Need to Know

By MedXY 09/15/2026

An international Delphi panel concludes metabolic dysfunction‑associated steatotic liver disease (MASLD) raises colorectal cancer (CRC) risk. Experts call for earlier, risk‑adapted CRC screening and integrated metabolic care to reduce CRC burden in patients with MASLD.

Diabetes & Endocrinology news Oncology

Impact of Hypercortisolism Severity on Outcomes in Adrenocortical Carcinoma with Cushing’s Syndrome

By MedXY 09/15/2026

This study reveals that the severity of hypercortisolism in adrenocortical carcinoma patients with Cushing’s syndrome correlates with higher metastatic risk and worse survival outcomes, highlighting its role as a marker of tumor aggressiveness.